Dr. Roberto A. Hernando, MD
Psychiatry (Psychiatry Physician)
- Medicare participating
At a glance
- Years since graduation
- 36
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 129
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Psychiatry Physician primary
FL license ME87473
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Jackson Health System Miami, FL
Medical groups
- Dade Family Counseling Community Mental Health Center, Inc (9 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 129
- Services billed
- 217
- Patients’ average age
- 68
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 289 | 149 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 263 | 46 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 83 | 64 |
| Hospital discharge day management, 30 minutes or less | 59 | 43 |
| Psychiatric diagnostic evaluation with medical services | 33 | 33 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Alprazolam Other prescribers in Miami, FL | 1,490 |
| Clonazepam Other prescribers in Miami, FL | 1,343 |
| Escitalopram Oxalate Other prescribers in Miami, FL | 1,186 |
| Quetiapine Fumarate Other prescribers in Miami, FL | 1,060 |
| Trazodone Hcl Other prescribers in Miami, FL | 953 |
| Temazepam Other prescribers in Miami, FL | 850 |
| Mirtazapine Other prescribers in Miami, FL | 642 |
| Venlafaxine Hcl Er (venlafaxine hcl) Other prescribers in Miami, FL | 490 |
| Lorazepam Other prescribers in Miami, FL | 475 |
| Sertraline Hcl Other prescribers in Miami, FL | 461 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 15 companies reported 107 payments worth $2,284 in total to this clinician.
| Teva Pharmaceuticals USA, Inc. | $318 |
|---|---|
| Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) | $264 |
| Janssen Pharmaceuticals, Inc | $254 |
| Neurocrine Biosciences, Inc. | $237 |
| Alkermes, Inc. | $223 |
| Takeda Pharmaceuticals U.S.A., Inc. | $201 |
| Otsuka America Pharmaceutical, Inc. | $193 |
| Almatica Pharma LLC | $183 |
| Food and Beverage | $2,175 |
|---|---|
| Education | $109 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. Mar 27, 2025 | Education in-kind | $109 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $419,952 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT06585787 - Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT05980949
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.